JPRN-UMIN000007423已完成未知
Infliximab(anti human TNF alfa monoclonal antibody, Remicade) off-label treatment for refractory Kawasaki disease - Infliximab treatment for refractory Kawasaki Disease
Department of Pediatrics, Saitama Medical Center, Saitama Medical University0 个研究点目标入组 5 人开始时间: 2012年3月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 18years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •congestive heart failure, severe infection, active tuberculosis, hypersensitivity for mouse-derived protein, demyelinating decease
研究者
相似试验
已完成
2 期
Infliximab effectiveness in COVID-19 patientsIRCT20201229049873N1Shahre-kord University of Medical Sciences40
已完成
2 期
Efficacy, Safety, and Tolerability Study of Infliximab in Juvenile SpondyloarthropathiesSpondylarthropathiesNCT00591201Hospital General de Mexico26
已完成
不适用
Pharmaco Kinetic Variability of Infliximab in Rheumatoid ArthritisRheumatoid ArthritisNCT00840957University Hospital, Tours84
已完成
不适用
Anti-TNF-alpha (Infliximab) in Complex Regional Pain SyndromeISRCTN75765780Erasmus Medical Centre (Netherlands)24
已完成
3 期
A Study of the Safety and Efficacy of Infliximab in Patients With PsoriasisPsoriasisNCT00106834Centocor, Inc.378